GUÍA DEL PROVEEDOR DE ATENCIÓN MÉDICA

Informe de la Prueba Myriad myRisk™ Cómo usar el informe para lograr resultados claros, accionables y que sirvan como guía

Impulsado por

Conocimiento preciso sobre los riesgos de cáncer. Orientación accionable para el manejo de los pacientes. La prueba myRisk™ de Myriad: • Evalúa un gran número de síndromes de cáncer hereditario • Combina los resultados del perfil genético con los antecedentes familiares y personales de cáncer para un seguimiento claro y accionable • Incluye recomendaciones de manejo para pacientes con resultados positivos o negativos basados en pautas establecidas por la sociedad médica, como la National Comprehensive Cancer Network (NCCN), la International Cancer of the Pancreas Screening (CAPS), el modelo de Claus para valoración del riesgo, los criterios de Amsterdan, entre otros • Se centra en ocho tipos de cáncer pasibles de tratamiento médico, lo que incluye cáncer de mama, colorrectal, gástrico, de endometrio, de páncreas, de próstata y melanoma

El informe de la prueba consiste en: • Resultado Genético myRisk • Herramienta de Manejo myRisk

2

Esquema de resultados: Estudio de caso Información sobre la paciente • Mujer de 36 años de edad • Alerta de riesgo por antecedentes familiares y personales de cáncer

Visita • Conversación sobre el manejo

C O N F I D EN T I A L CONF IDE NT IAL

myRisk Management Tool

Associated with:

Integrated BRACAnalysis® with Myriad myRisk™ Hereditary Cancer

Name: Patient Name

DOB: Jan 12, 1970

Accession #: 00001144-BLD

myRisk Genetic Result

Herramienta de Manejo myRisk Report Date: Jun 30, 2014

OVERVIEW

C O N F ID E N T IA L

RE C E I V IN G HEALTHC AR E P R OV IDE R

PAT I E N T

SPE CI M E N

Hereditary Breast and Ovarian Cancer Syndrome (HBOC): 

Physician Name, MD Specimen Type: Buccal • Healthcare This patient has been found to have mutation Jun in the BRCA1 Myriad Partners Draw aDate: 8, 2014 320 Wakara Way Accession Date: Jun 9, 2014 Hereditary Breast and Ovarian Cancer syndrome (HBOC). Salt Lake City, UT 84108 Report Date: Jun 30, 2014

Name:

Patient Name

Patient ID: Gender:

1144 Female

Name: Patient Name

Associated with:

DOB: Jan 12, 1970

Accession #: 00001144-BLD

Report Date: Jun 30, 2014

gene. Individuals withJan mutations Date of Birth: 12, 1970 in BRCA1 have a condition called

Resultado Genético myRisk

•

myRisk Management Tool

INFORMATION ON HOW CANCER RISKS AND MANAGEMENT ARE DETERMINED The myRisk Management Tool provides cancer risk levels based on analysis of genetic test results (see Genetic Test Report) and management

Women with HBOC have a high risk for developing breast and ovarian Accession cancer. There are also high risks for recommendations fallopian tube andof genetic test results and personal /family cancer history. Additional details can be found on based on acancer combined analysis #: 00001144-BLD www.MyriadPro.com. primary peritoneal cancer. Requisition #: 000000 O R D E R IN G P HY S IC IAN : Physician Name, MD • A comprehensive risk assessment may include other aspects of the patient’s personal/family medical history, as well as lifestyle, environment and other factors.

•

Men with HBOC due to mutations in BRCA1 have an elevated risk for breast and prostate cancer. The increased for prostate • Changesrisk in personal/family history or additional data regarding specific genes/mutations may affect the cancer risk estimates and management recommendations within this report. Personal/family history should be updated with a healthcare provider on a regular cancerRESULT: may be POSITIVE—CLINICALLY most significant at younger ages. basis. SIGNIFICANT MUTATION IDENTIFIED

•

Male and patients with HBOC due to inmutations anthat elevated risk for pancreatic cancer.and prostate cancers. African-American ethnicity, as reported on the test request form, was used in assessment for prostate cancer Note:female “CLINICALLY SIGNIFICANT, ” as defined this report,in is BRCA1 a genetichave change is associated with the

•

•

Management recommendations are provided for personal/family history of colorectal adenomas, breast, colorectal, melanoma, pancreatic management. Cancer risks and related management are included based on the gender provided.

potential to alter medical intervention.

Patients who have a clinical diagnosis of a genetic cancer syndrome (i.e., Hereditary Breast and Ovarian Cancer syndrome, Lynch Although there are high cancer risks for patients with HBOC, there are interventions that have been shown to be effective at reducing syndrome, etc.) may have different management recommendations than provided. Management should be personalized based on all known clinical diagnoses. risks. Guidelines from the NationalINTERPRETATION Comprehensive Cancer Network (NCCN) for the medical management of patients GENE many of these MUTATION • The Genetic Test Result Summary includes: female breast, male breast, colorectal, endometrial, gastric, melanoma, ovarian, pancreatic, and prostate cancer. In this summary with HBOC are listed below. It is recommended that patients with BRCA1 mutations and a diagnosis of HBOC be managed by aagene associated cancer risk is described as “High Risk” for a cancer type if all of the following conditions are met: the absolute cancer risk is 2% or higher, the increase in cancer risk over the general population is 3-fold or higher, and HIGH CANCER RISK c.68_69del (p.Glu23Valfs*17) there is substantive evidence supporting the cancer risk range. A gene is described as “Elevated Risk” for a cancer type if there are and of theand cancers with HBOC. This patient hastreatment Hereditary Breast Ovarianassociated Cancer (HBOC) BRCA1 multidisciplinary team with experience in the prevention

Heterozygous

•

sufficient data to support an increase in cancer risk over the general population risk, but not all criterion for “High Risk” are met.

syndrome.

DETAILS ABOUT: BRCA1 c.68_69del (p.Glu23Valfs*17): NM_007294.3; AKA: 187delAG

WHAT ARE THE PATIENT’S GENE-RELATED CANCER RISKS?

INFORMATION FOR FAMILY MEMBERS

Functional Significance: Deleterious – Abnormal Protein Production and/or Function

•

This patient’s relatives are at risk for carrying the same mutation(s) and associated cancer risks as this patient. Cancer risks for

femalesIf andthis males who have this/these IfThe more than onegermline gene mutation increases a specific cancer risk (e.g., breast), only the highest cancer riskatis shown. patient hasmutation(s) are provided below. heterozygous BRCA1 mutation c.68_69del is predicted to result in the premature truncation of the BRCA1 protein • Family members should talk to a healthcare provider about genetic testing. Closest relatives such as parents, children, more one gene mutation, risk estimates may be different, as this analysis does not account for possible interactions between amino than acid position 39 (p.Glu23Valfs*17). brothers, and sisters havegene the highest chance of having the same mutation(s) as this patient. Other more distant relatives such as cousins, aunts, uncles, and grandparents also have a chance for carrying the same mutation(s). Testing of at-risk relatives can mutations. identify those family members with the family specific mutation(s) who may benefit from surveillance and early intervention. Tools

Clinical Significance: High Cancer Risk This mutation is associated with increased cancer risk and should be regarded as clinically significant.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

CANCER TYPE

CANCER RISK

to aid in family testing are available at www.MySupport360.com.

RISK FOR GENERAL POPULATION

Details About Non-Clinically Significant Variants: All individuals carry DNA changes (i.e., variants) and most variants do not increase an individual’s riskBREAST of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign FEMALE variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most To likely do 50 not cause increased cancer risk. Present evidence does not that non-clinically significant variant findings be age Upsuggest to 51% 1.9% used to modify patient medical management beyond what is indicated by the personal and family history and any other significant To age 70 Up to 87% 7 .3% clinical findings. Variant Classification: myVision™ Reclassification Program20% continuously performs ongoing evaluations of variant Second primaryMyriad’s within 5 years of Variant first diagnosis 2.0% classifications. In certain cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid OVARIAN in variant classification. When new evidence about a variant is identified, that information will automatically be made available to the healthcare provider through an amended report.

RELATED TO

BRCA1 BRCA1 BRCA1

© 2014, Myriad Genetic Laboratories, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 800-469-7423 FX: 801-584-3615

To age 50

Up to 23%

0.2%

BRCA1

To age 70

Up to 44%

0.7%

BRCA1

12.7%

A) (3296C>A) T1099K

UNCERTAIN CLINICAL CLINICAL SIGNIFICANCE SIGNIFICANCE UNCERTAIN There are are currently currently insufficient insufficient data data to to determine determine ifif There these variants variants cause cause increased increased cancer cancer risk risk these

Details About About Non-Clinically Non-Clinically Significant Significant Variants: Variants: All All individuals individuals carry carry DNA DNA changes changes (i.e., (i.e., variants) variants) and and most most variants variants do do not not increase increase Details an individual’s individual’s risk risk of of cancer cancer or or other other diseases. diseases. When When identified, identified, variants variants of of uncertain uncertain significance significance (VUS) (VUS) are are reported. reported. Likely Likely benign benign an variants (Favor (Favor Polymorphisms) Polymorphisms) and and benign benign variants variants (Polymorphisms) (Polymorphisms) are are not not reported reported and and available available data data indicate indicate that that these these variants variants variants most likely likely do do not not cause cause increased increased cancer cancer risk. risk. Present Present evidence evidence does does not not suggest suggest that that non-clinically non-clinically significant significant variant variant findings findings be be most used to to modify modify patient patient medical medical management management beyond beyond what what isis indicated indicated by by the the personal personal and and family family history history and and any any other other significant significant used clinical findings. clinical findings. Variant Classification: Classification: Myriad’s Myriad’s myVision™ myVision™ Variant Variant Reclassification Reclassification Program Program continuously continuously performs performs ongoing ongoing evaluations evaluations of of variant variant Variant classifications. In In certain certain cases, cases, healthcare healthcare providers providers may may be be contacted contacted for for more more clinical clinical information information or or to to arrange arrange family family testing testing to to aid aid classifications. in variant variant classification. classification. When When new new evidence evidence about about aa variant variant isis identified, identified, that that information information will will automatically automatically be be made made available available to to the the in healthcare provider provider through through an an amended amended report. report. healthcare

ADDITIONAL INFORMATION INFORMATION ADDITIONAL GENES ANALYZED* ANALYZED* GENES APC APC ATM ATM

CDKN2A11 CDKN2A CHEK2 CHEK2

PMS2 PMS2 PTEN PTEN

BARD1 BARD1 BMPR1A BMPR1A

EPCAM EPCAM MLH1 MLH1

TP53 TP53 RAD51C RAD51C

BRCA1 BRCA1 BRCA2 BRCA2

MSH2 MSH2 MSH6 MSH6

RAD51D RAD51D SMAD4 SMAD4

BRIP1 BRIP1 CDH1 CDH1

MUTYH MUTYH NBN NBN

STK11 STK11

CDK4 CDK4

PALB2 PALB2

22

Unlessotherwise otherwisenoted notedsequencing sequencingand andlarge large Unless rearrangementanalyses analyseswere wereperformed performedon onthe theabove above rearrangement genes.Other Othergenes genesnot notanalyzed analyzedwith withthis thistest testmay mayalso also genes. Analysisof ofp16INK4a p16INK4aand and beassociated associatedwith withcancer. cancer.11Analysis be Largerearrangement rearrangementonly. only. p14ARF.22Large p14ARF.

Incluye información sobre la presencia de variantes genéticas de importancia incierta que no se consideran clínicamente significativas. Cuando surjan nuevos datos sobre una variante, el proveedor de atención médica recibirá un informe enmendado que incluirá la información actualizada.

Indication for for Testing: Testing: ItIt isis our our understanding understanding that that this this individual individual was was identified identified for for testing testing Indication due to to aa personal personal or or family family history history suggestive suggestive of of aa hereditary hereditary predisposition predisposition for for cancer. cancer. due Associated Cancer Cancer Risks Risks and and Clinical Clinical Management: Management: Please Please see see the the “Cancer “Cancer Risk Risk and and Associated Management Tool” Tool” associated associated with with this this report report for for aa summary summary of of cancer cancer risk risk and and professional professional Management society medical medical management management guidelines guidelines that that may may be be useful useful in in developing developing aa plan plan for for this this society patient based based on on test test results results and and reported reported personal personal and/or and/or family family history, history, ifif applicable. applicable. Testing Testing patient of other other family family members members may may assist assist in in the the interpretation interpretation of of this this patient’s patient’s test test result. result. of Analysis Description: Description: The The Technical Technical Specifications Specifications summary summary (www.MyriadPro.com) (www.MyriadPro.com) Analysis describes the the analysis, analysis, method, method, performance, performance, nomenclature, nomenclature, and and interpretive interpretive criteria criteria of of this this describes test. *The *The classification classification and and interpretation interpretation of of all all variants variants identified identified in in this this assay assay reflects reflects the the test. current state of scientific understanding at the time this report was issued, and may change as current state of scientific understanding at the time this report was issued, and may change as new scientific scientific information information becomes becomes available. available. new Please contact contact Myriad Myriad Professional Professional Support Support at at 1-800-469-7423 1-800-469-7423 Please to discuss discuss any any questions questions regarding regarding this this result. result. to

2014,Myriad MyriadGenetic GeneticLaboratories, Laboratories,Inc. Inc. | | 320 320Wakara WakaraWay, Way,Salt SaltLake LakeCity, City,Utah Utah84108 84108 | | PH: PH:800-469-7423 800-469-7423 FX: FX:801-584-3615 801-584-3615 ©©2014,

Page11of of22 myRiskGenetic GeneticResult: Result:Page myRisk

Las variantes genéticas de importancia incierta no son actualmente accionables; la evidencia disponible no sugiere que estas variantes deban usarse para cambiar el manejo médico del paciente. Las variantes, Indica Polimorfismo/ Polimorfismo son variantes genéticas para las cuales los datos disponibles indican que es muy poco probable que alteren la producción y/o la función de las proteínas o que contribuyan de modo significativo al riesgo de cáncer. No se incluye información sobre este tipo de variantes.

5

Positivo: Herramienta de Manejo myRisk C O N F I DE N T I AL

Integrated BRACAnalysis® with Myriad myRisk™ Hereditary Cancer

myRisk Management Tool RECEIVING HEA LTH C A R E P R O V I D ER

S P EC I MEN

Physician Name, MD Myriad Healthcare Partners 320 Wakara Way Salt Lake City, UT 84108

Specimen Type: Draw Date: Accession Date: Report Date:

PATI ENT

Name: Date of Birth: Patient ID: Gender: Accession #: Requisition #:

Buccal Jun 8, 2014 Jun 9, 2014 Jun 30, 2014

ORDERING PHYS I C I A N: Physician Name, MD

Patient Name Jan 12, 1970 1144 Female 00001144-BLD 000000

GENETIC TEST RESULTS SUMMARY INFORMATION RESULT: POSITIVE—CLINICALLY SIGNIFICANT MUTATION IDENTIFIED

Los pacientes recibirán una visión sintética de los resultados genéticos y los niveles de riesgo de cáncer asociados para ocho tipos de cáncer.

Note: “CLINICALLY SIGNIFICANT,” as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED GENE

T H I S G E NE T I C T E ST RE SU LT I S A SSO CI AT E D WITH THE FO LLO WI NG CA NCE R RI SKS:

MU TAT I O N

BRCA1

c.68_69del (p.Glu23Valfs*17)

HIGH RISK: Female Breast, Ovarian ELEVATED RISK: Pancreatic

Los antecedentes personales y/o familiares suministrados se emplean para la evaluación del riesgo basado en antecedentes familiares. El símbolo en el recuadro naranja indica que algo requiere atención por parte del proveedor de atención médica. Si corresponde, se brinda información sobre manejo modificado en las páginas subsiguientes.

PERSONAL / FAMILY HISTORY SUMMARY AND MANAGEMENT INFORMATION FAM ILY M EM BER

CA NCE R / CLI NI CA L D I A G NO SI S

A G E AT D I A G NO SI S

Patient

None

Mother

Breast

45

Maternal Aunt

Breast

55

MODIFIED MEDICAL MANAGEMENT MAY BE APPROPRIATE

This information was provided by a qualified healthcare provider on the test request form and was not verified by Myriad.

© 2014, Myriad Genetic Laboratories, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 800-469-7423 FX: 801-584-3615

6

myRisk Management Tool: Page 1 of 5

En informes con un resultado positivo, la Herramienta de Manejo myRisk combina la información genética con los antecedentes familiares para ofrecer consideraciones de manejo basadas en las pautas generales Herramienta de Manejo basada en pautas generales

CO N FI D E N T I A L

myRisk Management Tool Name: Patient Name

Associated with:

DOB: Jan 12, 1970

Accession #: 00001144-BLD

Report Date: Jun 30, 2014

CO N FI D E N T I A L

WHAT MANAGEMENT FOR CANCER RISKS SHOULD BE CONSIDERED?

myRisk Management Tool

Associated with:and genetic test results. Unless otherwise stated, Clinical management guidelines are based on this patient’s personal and family history management guidelines included below are limited to those issued by the National Comprehensive Cancer Network (NCCN). See the Name: Patient Name DOB: Jan 12, 1970 Accession #: 00001144-BLD Report Date: Jun 30, 2014 reference listed for more details. If management for a specific cancer (e.g., breast) is available due to multiple causes (e.g., a mutation and a family history, or multiple mutations in different genes), only the most aggressive management isFI shown. related to CO N D E NGuidelines TIAL the patient’s long-term care for cancer prevention are included. Guidelines for the treatment of an existing cancer are not included. Any OVERVIEW discussion of medical management options is for general informational purposes only and does not constitute Associated with: a recommendation. While Hereditary Breastguidelines and Ovarian Cancer Syndrome (HBOC):  genetic testing and medical society provide important and useful information, medical management decisions should be made in consultation between each patient and his or her healthcare provider. Name: Patient Name DOB: Jan 12, 1970 Accession #: 00001144-BLD Report Date: Jun 30, 2014 • This patient has been found to have a mutation in the BRCA1 gene. Individuals with mutations in BRCA1 have a condition called

myRisk Management Tool

Hereditary Breast and Ovarian Cancer syndrome (HBOC). • PROCEDURE

Women with HBOC have a high risk for developing breast and ovarian cancer. There F R Eare Q U Ealso N C Yhigh risks for fallopian tube cancer and primary peritoneal cancer. AGE TO BEGIN (Unless otherwise R E L AT E D T O

indicated by findings) Men with HBOC due to mutations in BRCA1 haveCLINICALLY an elevated risk for breast and prostate cancer. The increased risk for prostate CANCER RISK FOR BRCA1 SIGNIFICANT MUTATION cancer may be most significant at younger ages. FEMALE BREAST • Women Male and female with due to mutations in BRCA1 have an elevatedCrisk cancer. R I S K F O R G E N E R A L P O P U L AT IO N Breast awarenessshould be patients familiar C A N C E Rwith T Y PHBOC E A N for C E Rpancreatic RISK their breasts and report changes tocancer their risks for patients with HBOC, there are interventions that have been shown to be effective at reducing • promptly Although there are high 18 years NA BRCA1 healthcare provider. many Periodic, consistent self- from the National Comprehensive Cancer of these risks.breast Guidelines forI Vthe F ONetwork R F E M A L(NCCN) E R E L AT E S medical management of patients examination (BSE) may breast awareness withfacilitate HBOC are listed below. It1is recommended that patients with BRCA1 mutations and a diagnosis of HBOC be managed by a FEMALE BREAST and treatment of the cancers Clinical breast exam1multidisciplinary team with experience in the prevention 25 years Every 6 toassociated 12 monthswith HBOC. BRCA1 •

Las recomendaciones para el manejo clínico provienen de la National Comprehensive Cancer Network (NCCN) así como de otros grupos de consenso y especialidad.

To age 50

25 years, or individualized based on

Mammography and Breast MRI1

earliest diagnosis in family To age 70 WHAT ARE THE PATIENT’S GENE-RELATED CANCER RISKS?

To 5age 70 of first diagnosis Second primary within years

VAspecific RI A N medical management Currently there areOno guidelines for pancreatic cancer risk PA N C R E AT I C To age 50 1.

20%

To age 80

7.3%

BRCA1

8.2%

BRCA1

Elevated Risk

BRCA1

12.7%

20% lifetime risk)

Consider breast MRI in addition to mammography1,2

30 years

Annually

Family History (>20% lifetime risk)

Individualized

NA

Family History (>20% lifetime risk)

Individualized

NA

Uncertain Variant(s)

PRO CED U RE

FEMA LE B REA S T Breast Awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast selfexamination (BSE) may facilitate breast awareness1

Consider risk reduction strategies1,2 O TH ER CO N SID E R AT I ON S One or more Variants of Uncertain Significance (VUS) were identifed (see myRisk Genetic Result). Recommend clinical management based on personal / family history and other risk factors. 1.

Bevers TB, et al. NCCN Clinical Practice Guidelines in Oncology®: Breast Cancer Screening and Diagnosis. V 2.2013. July 3. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf.

2.

Claus EB, et al. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994 73:643-51. PMID: 8299086.

Notes for Personalized Management:

© 2014, Myriad Genetic Laboratories, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 800-469-7423 FX: 801-584-3615

myRisk Management Tool: Page 2 of 3

No se evalúan los cánceres personales para las consideraciones de riesgo y manejo.

Las consideraciones de manejo médico que se suministran solo pretenden presentar aspectos generales y se ofrecen con fines informativos. El cuidado efectivo del paciente es responsabilidad del médico tratante y debe basarse en una cuidadosa revisión de todos los factores asociados con el paciente así como la consideración de las referencias aquí mencionadas y otros recursos.

9

Cuadro de genes y tipos de cáncer asociados • Se analizan los genes que poseen riesgos de cáncer establecidos y son clínicamente accionables • L a selección de los genes se centra en ochos tipos de cáncer basados en la superposición de la contribución hereditaria y el síndrome Tipos de cáncer asociados* Genes

de mama

de ovario

colorrectal

de endometrio

melanoma

de páncreas

gástrico

BRCA1, BRCA2 MLH1, MSH2, MSH6, PMS2, EPCAM† STK11 APC, BMPR1A, SMAD4 MUTYH CDK4, CDKN2A TP53 PTEN CDH1 PALB2, ATM CHEK2 NBN BARD1 BRIP1, RAD51C RAD51D

*Las mutaciones genéticas podrían estar asociadas con otros tipos de cáncer y características clínicas. † Solo grandes reorganizaciones

10

de próstata

Otro

Optimice el cuidado de los pacientes con resultados precisos y confiables De Myriad, su asesor de confianza • Líder mundial en cáncer hereditario • Más de 20 años de experiencia en pruebas genéticas para el cáncer • Más de 1 millón de pacientes evaluados • Más de 60,000 proveedores han elegido las pruebas de Myriad

Desempeño del más alto nivel Sensibilidad analítica del ~99.92%1* • Confianza como elpatrón de oro de la calidad • Los estudios de validación muestran una concordancia del 100% con el método Sanger para la secuenciación y análisis de las grandes reorganizaciones

Optimización de la prueba • Diseño optimizado de biblioteca de cebadores NGS para aumentar la sensibilidad y especificidad de la prueba • Complementado con múltiples técnicas personalizadas (p. ej. microarreglos específicos)

Impulsado por la tecnología de clasificación de variantes myVision™ • Compromiso de por vida con la interpretación precisa de las variantes • Más de 1 millón de dólares invertidos en el desarrollo de técnicas de clasificación de variantesy una base de datos curada respaldada por más de 30 científicos • Técnicas para la clasificación de variantes validadas y con una precisión de más del 99% exclusivas de Myriad2,3 *Límite inferior del >99.92% intervalo de confianza del 95%. 1. Roa B, Bowles K, Bhatnagar S, et al. Development of a next generation sequencing panel to assess hereditary cancer risk that includes clinical diagnostic analysis of the BRCA1 and BRCA2 genes. Poster presented at: American Society of Human Genetics 2013 Annual Meeting, October 22-26, 2013, Boston, MA. 2. Bowles KR, Morris B, Hughes E, et al. A clinical history weighting algorithm accurately classifies BRCA1 and BRCA2 variants. Poster presented at: American Society of Human Genetics 2013 Annual Meeting, October 22-26, 2013, Boston, MA. 3. Eggington J, Bowles K, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet. 2013 Nov 8. doi: 10.1111/cge.12315. [Epub ahead of print].

11

La ventaja Myriad: apoyo del más alto nivel Apoyo financiero • Los pacientes más apropiados pagan $0 • S i sus pacientes tienen inquietudes cuando reciben una factura de Myriad, pueden llamar al número de teléfono que aparece en la factura. Le garantizamos que trabajaremos juntos para encontrar una solución • L os pacientes no asegurados que cumplen con los requisitos médicos y financieros específicos pueden participar en el Programa de Asistencia Financiera Myriad

Apoyo para pacientes •A  través del programa en línea MySupport360®, Myriad pone a su pacientes en contacto con una gran cantidad de información de utilidad, consejos expertos y la posibilidad de compartir sus experiencia con otras personas

Apoyo para médicos •U  n equipo de especialistas médicos altamente capacitados está disponible para consultas • P uede acceder a estos servicios de apoyo por teléfono, correo electrónico o en persona

Visite www.MyriadPro.com para acceder a una amplia gama de recursos y educación médica

Myriad Genetic Laboratories, Inc. 320 Wakara Way Salt Lake City, UT 84108 1-800-469-7423

Myriad, el logotipo de Myriad, Myriad myRisk Hereditary Cancer, el logotipo de Myriad myRisk Hereditary Cancer, Myriad Promise, el logotipo de Myriad Promise, MySupport360 y el logotipo de MySupport360 son marcas comerciales o marcas registradas de Myriad Genetics, Inc. en los Estados Unidos y en otras jurisdicciones.

12

©2014, Myriad Genetic Laboratories, Inc. MRRPTOVWSP/06-14